Food and Drug Administration, HHS.
Notice.Start Printed Page 38714
This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.
Name of Committee: Anesthetic and Life Support Drugs Advisory Committee.
General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on September 13 and 14, 2001, from 8 a.m. to 5 p.m.
Location: University of Maryland, Shady Grove Campus, multi-purpose room, Bldg. 9630, Gudelsky Dr., Rockville, MD.
Contact: Kimberly Littleton Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1091), Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12529. Please call the Information Line for up-to-date information on this meeting.
Agenda: On both days, the committee will discuss the medical use of opiate analgesics in various patient populations, including pediatric patients and patients with chronic pain of nonmalignant etiology, as well as the risk to benefit ratio of extending opiate treatment into these populations. It will also address concerns regarding the abuse potential, diversion and increasing incidence of addiction to opiate analgesics, especially to the modified release opiate analgesics.
Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by August 17, 2001. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on September 13, 2001, and between approximately 9 a.m. and 10 a.m. on September 14, 2001. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before August 17, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).Start Signature
Dated: July 19, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-18478 Filed 7-24-01; 8:45 am]
BILLING CODE 4160-01-S